» Articles » PMID: 35435642

Dopamine D3 Receptor, Cognition and Cognitive Dysfunctions in Neuropsychiatric Disorders: From the Bench to the Bedside

Overview
Publisher Springer
Specialty Psychology
Date 2022 Apr 18
PMID 35435642
Authors
Affiliations
Soon will be listed here.
Abstract

The dopamine D3 receptor (D3R) plays a prominent role in the modulation of cognition in healthy individuals, as well as in the pathophysiological mechanism underlying the cognitive deficits affecting patients suffering from neuropsychiatric disorders. At a therapeutic level, a growing body of evidence suggests that the D3R blockade enhances cognitive and thus it may be an optimal therapeutic strategy against cognitive dysfunctions. However, this is not always the case because other ligands targeting the D3R, and behaving as partial agonists or biased agonists, may exert their pro-cognitive effect by maintaining adequate level of dopamine in key brain areas tuning cognitive performances. In this chapter, we review and discuss preclinical and clinical findings with the aim to remark the crucial role of the D3R in cognition and to strengthen the message that drugs targeting D3R may be excellent cognitive enhancers for the treatment of several neuropsychiatric and neurological disorders.

Citing Articles

Exploring cariprazine as a treatment option for varied depression symptom clusters.

Pejuskovic B, Munjiza Jovanovic A, Pesic D Front Psychiatry. 2024; 15:1442699.

PMID: 39386892 PMC: 11461305. DOI: 10.3389/fpsyt.2024.1442699.


D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside.

Barabassy A, Dombi Z, Nemeth G Int J Mol Sci. 2024; 25(11).

PMID: 38891871 PMC: 11172134. DOI: 10.3390/ijms25115682.


Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.

Jenner P, Falup-Pecurariu C, Leta V, Verin M, Auffret M, Bhidayasiri R J Neural Transm (Vienna). 2023; 130(11):1337-1347.

PMID: 37210460 PMC: 10645644. DOI: 10.1007/s00702-023-02655-0.